ImmuPharma (LON:IMM) Shares Down 18% – Here’s Why

ImmuPharma plc (LON:IMM) was down 18% on Monday . The company traded as low as GBX 3.52 and last traded at GBX 3.60. Approximately 1,204,775 shares were traded during mid-day trading, a decline of 53% from the average session volume of 2,577,156 shares. The stock had previously closed at GBX 4.39.

ImmuPharma Stock Performance

The stock has a market capitalization of £22.34 million, a price-to-earnings ratio of -9.68 and a beta of 3.02. The company has a fifty day simple moving average of GBX 4.06 and a 200 day simple moving average of GBX 5.

ImmuPharma (LON:IMM) last issued its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. As a group, equities analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.